Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Sees Significant Growth in Short Interest

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 11,000 shares, an increase of 46.7% from the January 15th total of 7,500 shares. Based on an average trading volume of 2,200 shares, the days-to-cover ratio is presently 5.0 days.

Clinuvel Pharmaceuticals Trading Up 2.7 %

Shares of CLVLY stock opened at $7.50 on Friday. The firm’s 50-day simple moving average is $7.54 and its 200-day simple moving average is $8.71. Clinuvel Pharmaceuticals has a 1-year low of $6.80 and a 1-year high of $11.40.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).